Trinity Biotech (TRIB) Cash from Financing Activities (2021 - 2024)

Trinity Biotech has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $1.8 million for Q4 2024.

• Cash from Financing Activities for Q4 2024 came in at $1.8 million, up 202.21% year-over-year; the trailing twelve-month figure through Dec 2024 was -$4.2 million (up 49.64% YoY), and the FY2025 annual result was $12.1 million, down 58.17% from the prior year.
• Cash from Financing Activities came in at $1.8 million for Q4 2024 at Trinity Biotech, up from -$1.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.8 million in Q4 2024 to a low of -$3.6 million in Q4 2021.
• The 4-year median for Cash from Financing Activities is -$2.1 million (2022), against an average of -$1.7 million.
• Across the five-year window, Cash from Financing Activities declined 2.49% in 2023 and jumped 202.21% in 2024, its largest moves.
• Trinity Biotech's Cash from Financing Activities stood at -$3.6 million in 2021, then soared by 48.56% to -$1.8 million in 2022, then grew by 4.28% to -$1.8 million in 2023, then surged by 202.21% to $1.8 million in 2024.
• The last three Cash from Financing Activities figures came in at $1.8 million (Q4 2024), -$1.8 million (Q4 2023), and -$2.4 million (Q3 2023), per Business Quant data.